Direct Coombs Test (DCT) Antibody Market Report 2026

The direct coombs test (dct) antibody market size has grown rapidly in recent years. It will grow from $6.55 billion in 2025 to $7.3 billion in 2026 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to growth in biomedical research funding, rising prevalence of cancer research programs, expansion of academic laboratory infrastructure, increased use of antibodies in diagnostics, improvements in antibody engineering techniques.

The direct coombs test (dct) antibody market size is expected to see rapid growth in the next few years. It will grow to $11.17 billion in 2030 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to expansion of precision oncology research, increasing demand for next-generation antibody formats, rising investments in biologics manufacturing, growth of personalized medicine applications, advances in antibody discovery platforms. Major trends in the forecast period include increasing use of recombinant antibody technologies, growing demand for high-specificity monoclonal antibodies, expansion of antibody applications in oncology research, rising adoption of bispecific antibody formats, enhanced focus on scalable antibody production.

The rising demand for personalized medicine is expected to drive growth in the direct Coombs test (DCT) antibody market going forward. Personalized medicine tailors treatments to individual patients based on genetic, environmental, and lifestyle factors to optimize outcomes and improve care. This demand is increasing due to advancements in genomic technologies, which allow precise identification of genetic variations and the development of tailored treatments. Direct Coombs test (DCT) antibodies support personalized medicine by enabling accurate detection of antibodies or complement bound to red blood cells. This facilitates the identification of immune-mediated hemolytic conditions, allowing clinicians to customize treatments based on a patient’s specific immune profile, thereby enhancing diagnostic accuracy and therapeutic outcomes. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, up from 12 in 2022. Therefore, the increasing demand for personalized medicine is fueling the growth of the direct Coombs test (DCT) antibody market.

Companies in the direct Coombs test (DCT) antibody market are emphasizing technological innovation, such as gel-based immunoassays, to improve reliability, streamline laboratory workflows, and maintain high standards in pre-transfusion testing. Gel-based immunoassays involve the interaction of antibodies and antigens within a gel matrix, enabling visual detection of reactions such as agglutination. For instance, in October 2025, QuidelOrtho Corporation, a US-based in-vitro diagnostics company, received FDA clearance for its MTS DAT Card for gel-based direct antiglobulin testing on the ORTHO VISION platform. The card contains anti-IgG and anti-C3d monospecific reagents in separate gel microtubes, allowing clear differentiation between IgG and complement sensitization. This design simplifies the investigation of immune-mediated hemolytic anemias and hemolytic disease of the fetus and newborn (HDFN), supporting hemolysis detection and improving transfusion safety.

In March 2023, Werfen Life Sciences S.A., a Spain-based in-vitro diagnostics company, acquired Immucor Inc. for approximately $2 billion. Through this acquisition, Werfen aims to enhance its leadership in transfusion medicine by integrating Immucor’s immunohematology portfolio, expanding automation, increasing global reach, and improving patient safety in hemolysis detection and transfusion management. Immucor Inc., based in the US, specializes in Direct Coombs Test (DCT) antibody and immunohematology diagnostics.

Major companies operating in the direct coombs test (dct) antibody market are Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bio-Rad Laboratories Inc., Fortress Diagnostics Limited, Lab-Care Diagnostics (India) Pvt. Ltd., SIFIN Diagnostics GmbH, Hemo Bioscience Inc., Rapid Labs Ltd, AnaMol Laboratories Pvt. Ltd., Jiangyin Libo Biotechnology Co. Ltd., MicroSidd India Pvt. Ltd., Atlas Medical GmbH, Lorne Laboratories Ltd, Sanquin Reagents B.V., BAG Diagnostics GmbH, CE-Immundiagnostika GmbH, Biolab Diagnostics (India) Pvt. Ltd., Singapore Biosciences Pte. Ltd.

North America was the largest region in the direct coombs test (DCT) antibody market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the direct coombs test (dct) antibody market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the direct coombs test (dct) antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the direct coombs test antibody market by increasing costs of imported reagents, expression systems, purification equipment, and analytical instruments used in antibody production and validation. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to dependence on imported life science tools, while Asia-Pacific faces cost pressures on recombinant antibody manufacturing. These tariffs are increasing production costs and extending development timelines. However, they are also promoting local reagent manufacturing, regional bioprocessing capacity expansion, and domestic investment in antibody research infrastructure.

The direct coombs test (dct) antibody market research report is one of a series of new reports that provides direct coombs test (dct) antibody market statistics, including direct coombs test (dct) antibody industry global market size, regional shares, competitors with a direct coombs test (dct) antibody market share, detailed direct coombs test (dct) antibody market segments, market trends and opportunities, and any further data you may need to thrive in the direct coombs test (dct) antibody industry. This direct coombs test (dct) antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A direct Coombs test (DCT) antibody is an antibody that specifically recognizes the dopachrome tautomerase (DCT) protein, also known as tyrosinase-related protein 2 (TRP-2). This protein is crucial in melanin biosynthesis and serves as a marker for melanocyte differentiation and melanoma research. DCT antibodies are widely used to detect, quantify, and study DCT expression in biological samples.

The main types of direct Coombs test (DCT) antibodies are monoclonal antibodies, polyclonal antibodies, recombinant antibodies, and bispecific antibodies. Monoclonal antibodies are laboratory-produced molecules engineered to bind specifically to antigens on red blood cells, allowing precise detection of immune-mediated hemolysis in diagnostic testing. These antibodies are sourced from human, mouse, rabbit, other mammals, or recombinant origins. They are applied in areas such as cancer research, autoimmune diseases, infectious diseases, transplant rejection, and related studies. Key end-users include pharmaceutical companies, biotechnology firms, contract research organizations (CROs), academic and research institutes, and diagnostic laboratories.

The direct coombs test (DCT) antibody consists of sales of primary antibodies, secondary antibodies, antibody kits, assay reagents, western blot reagents, enzyme-linked immunosorbent assay (ELISA) kits, immunohistochemistry kits, ready-to-use detection kit, anti- direct coombs test (DCT) (TRP-2), and rabbit monoclonal primary antibody. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.